Based on the Myriad Genetics Inc stock forecast from 11 analysts, the average analyst target price for Myriad Genetics Inc is USD 19.79 over the next 12 months. Myriad Genetics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Myriad Genetics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Myriad Genetics Inc’s stock price was USD 8.07. Myriad Genetics Inc’s stock price has changed by -9.02% over the past week, -20.73% over the past month and -60.32% over the last year.
No recent analyst target price found for Myriad Genetics Inc
No recent average analyst rating found for Myriad Genetics Inc
Company Overview Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Read Less
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides...Read More
Frequently Asked Questions About Myriad Genetics Inc (MYGN) Stock
Based on ratings from 11 analysts Myriad Genetics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, 2 sell and 10 hold ratings.
Unfortunately we do not have enough data on MYGN's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for MYGN is USD 19.79 over the next 12 months. The maximum analyst target price is USD 34 while the minimum anlayst target price is USD 11.
MYGN stock's Price/Earning ratio is 31.74.
Our analysis grades MYGN stock's Price / Earning ratio at F. This means that MYGN stock's Price/Earning ratio is above 61% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this MYGN may be a overvalued for its sector.
The last closing price of MYGN's stock was USD 8.07.
The most recent market capitalization for MYGN is USD 0.74B.
Based on targets from 11 analysts, the average taret price for MYGN is projected at USD 19.79 over the next 12 months.
This means that MYGN's stock price may go up by +145.22% over the next 12 months.
We can't find any ETFs which contains Myriad Genetics Inc's stock.
As per our most recent records Myriad Genetics Inc has 2,700 Employees.
Myriad Genetics Inc's registered address is 322 North 2200 West, Salt Lake City, UT, United States, 84116.
You can get more information about it from Myriad Genetics Inc's website at https://www.myriad.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Myriad Genetics Inc (MYGN) Stock
Based on ratings from 11 analysts Myriad Genetics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, 2 sell and 10 hold ratings.
Unfortunately we do not have enough data on MYGN's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for MYGN is USD 19.79 over the next 12 months. The maximum analyst target price is USD 34 while the minimum anlayst target price is USD 11.
MYGN stock's Price/Earning ratio is 31.74.
Our analysis grades MYGN stock's Price / Earning ratio at F. This means that MYGN stock's Price/Earning ratio is above 61% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this MYGN may be a overvalued for its sector.
The last closing price of MYGN's stock was USD 8.07.
The most recent market capitalization for MYGN is USD 0.74B.
Based on targets from 11 analysts, the average taret price for MYGN is projected at USD 19.79 over the next 12 months.
This means that MYGN's stock price may go up by +145.22% over the next 12 months.
We can't find any ETFs which contains Myriad Genetics Inc's stock.
As per our most recent records Myriad Genetics Inc has 2,700 Employees.
Myriad Genetics Inc's registered address is 322 North 2200 West, Salt Lake City, UT, United States, 84116.
You can get more information about it from Myriad Genetics Inc's website at https://www.myriad.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MYGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
